How to Conduct Post-Market Surveillance for Medical Devices in Australia?

Key Summary

Once a medical device enters the Australian market, the registration holder must legally conduct post-market surveillance (PMS) throughout the product lifecycle. The Therapeutic Goods Administration (TGA) requires the holder to establish and maintain a quality management system (QMS) that includes adverse event reporting, complaint handling, field safety corrective actions (FSCA), product update notifications, and periodic safety update reports (PSUR). Companies must develop differentiated PMS plans based on product classification (Class I, IIa, IIb, III, and AIMD): low-risk products may simplify processes, while medium- and high-risk products must submit annual reports or PSURs. Core documentation includes: PMS plan, medical device reports (MDR), FSCA records, CAPA records, post-market clinical follow-up (PMCF) reports (if applicable), and product change notifications (e.g., design or intended use changes). Common mistakes include: failing to report serious adverse events in a timely manner (TGA requires an initial report within 24 hours and a complete report within 10 days), confusing PMS with post-market clinical studies, not designating a local authorized representative (Sponsor) responsible for PMS, and neglecting to archive updated labels and instructions for use. Companies should establish PMS SOPs in advance, designate personnel to interface with the TGA, and ensure that ISO 13485 or MDSAP systems cover PMS requirements. For multinational registrations, Australian PMS data can be reused in connection with databases from other regulators (e.g., European CE, US FDA, China NMPA), but attention must be paid to differences in definitions and timelines for special adverse events in Australia. The local Sponsor bears legal responsibility for PMS compliance; companies must not bypass the Sponsor to communicate directly with the TGA. Post-market surveillance is not only a regulatory obligation but also a key element for continuous product safety and performance improvement.

Applicable Scenarios and Core Issues

This FAQ applies to all medical device manufacturers and local Sponsors who have obtained registration (ARTG listing) with the Australian Therapeutic Goods Administration (TGA). PMS covers the entire product lifecycle from market entry to withdrawal and applies to all risk classes: Class I (self-declared), IIa/IIb/III, and AIMD (active implantable medical devices). Core issues include: what triggers PMS activities? What documents need to be submitted? How are adverse events classified and reported? How are responsibilities divided between the Sponsor and the manufacturer? Are there annual or periodic reporting requirements? How can registration be maintained after product changes? The legal framework for Australian PMS is based on the Therapeutic Goods Act 1989 and its amendments, as well as the TGA's Medical Device Post-Market Surveillance Guidance. Manufacturers and Sponsors must jointly ensure the ongoing safety and effectiveness of devices while sold in Australia. The TGA oversees compliance through audits, market sampling, adverse event analysis, and a product vigilance system. Companies should note: PMS is not the same as a post-market clinical study; the former is systematic data collection and analysis, while the latter is a prospective investigation with a study protocol. For high-risk products, the TGA may require a post-market clinical follow-up (PMCF) plan as part of PMS.

Registration Decision Logic

Intensity and Requirements by Risk Class

• Class I (exempt/non-sterile/no measuring function): Generally only require complaint handling and adverse event records within the QMS; no PSUR submission needed, but ARTG must be updated after any changes.
• Class I (sterile/measuring function), IIa, IIb, III, and AIMD: Must establish a written PMS plan and submit PSUR as required (IIb/III every 2 years, AIMD annually). The PMS plan must include passive monitoring (complaints, feedback) and active data collection (literature, database queries).
• IIb/III and AIMD: Also need to consider a PMCF plan, especially for novel materials, long-term implants, or devices lacking clinical data.

Key Principles

• Irrespective of sponsor responsibilities: PMS obligations cannot be transferred, even if the product is exempt from GMP. Manufacturers must ensure their QMS (e.g., ISO 13485) covers PMS requirements and that clear agreements exist with the Sponsor.
• Multinational reuse: If the product has CE, FDA, or NMPA registration, its PMS data and reports can serve as the basis for Australian submissions, but must be adjusted to TGA requirements (e.g., TGA requires 24-hour initial report vs. EU's 48 hours).
• Post-change assessment: Any design, manufacturing, intended use, packaging, or labeling changes require re-evaluation of the PMS plan; a PSUR or variation application may be necessary.

Documentation and Evidence

Post-market surveillance requires the following documents to be maintained and submitted to the TGA on a scheduled or ad-hoc basis:

• PMS plan: includes data collection methods, frequency, responsibility assignment, and data analysis rules.
• Adverse event reports (MDR): classified as serious adverse device events (SADE) or non-serious. Serious events require initial report within 24 hours and complete report within 10 days.
• Field safety corrective action (FSCA) notifications: include recalls, product use suspensions, warning letters, etc.
• Corrective and preventive action (CAPA) records.
• Periodic safety update report (PSUR): includes post-market data summary, risk analysis, and evaluation of corrective measure effectiveness.
• Post-market clinical follow-up (PMCF) report (if applicable): clinical tracking data, literature review, and database analysis.
• Product change records and supporting documents.
• Complaint handling records and trend analysis.
• Revision history of labels and instructions for use.

The TGA may request any of the above documents at any time or conduct an on-site inspection. Records must be retained for at least 10 years from the date the product is withdrawn from the market.

Common Mistakes

• Ignoring the 24-hour initial report deadline: Some companies mistakenly wait until the cause is determined before reporting serious adverse events, leading to delays.
• Confusing Sponsor and manufacturer responsibilities: The Sponsor is the TGA's sole point of contact, but technical PMS assessments are led by the manufacturer; both must have a clear agreement.
• Failing to establish active monitoring processes: Relying solely on passive complaints, lacking literature searches, database scans, and proactive communication.
• Incomplete PSUR content or missed submissions: PSUR must include global market data, not just Australia.
• Failing to update ARTG after product changes: Any change affecting safety or performance requires prior approval or notification.
• Confusing PMS with PMCF: PMS is mandatory; PMCF is recommended but often required for high-risk products.

Company Preparation Checklist

• □ Develop and approve a PMS plan (including risk class-specific requirements).
• □ Appoint an Australian Sponsor and sign a contract defining PMS responsibilities.
• □ Establish SOPs for adverse event receipt, assessment, and reporting.
• □ Establish SOPs for initiating and reporting FSCA.
• □ Establish a process for product change assessment and registration update.
• □ Create a schedule for PSUR drafting, review, and submission.
• □ Ensure QMS (ISO 13485 or MDSAP) includes PMS elements.
• □ Retain global PMS data for cross-market reuse.
• □ Train employees (manufacturer and Sponsor) on TGA regulations.
• □ Conduct periodic internal audits or mock TGA inspections.

AIMEILI Regulatory Interpretation and Business Impact

Companies often mistakenly believe that PMS applies only to high-risk products or only when adverse events occur. In reality, the TGA requires PMS records for all risk classes; low-risk products can simplify the process but cannot skip it. In the early stages of a project, priority should be given to three tasks: first, sign a detailed responsibility agreement with the Sponsor, clarifying PMS data transfer and reporting processes; second, draft a PMS plan based on product classification and risk characteristics, even before market launch, to allow early planning; third, check whether the existing ISO 13485 system covers PMS requirements (many companies' systems only cover design and production, ignoring the post-market phase). Reusable documents include: EU CE post-market surveillance plans, FDA adverse event databases, and China NMPA adverse event records. Items that must be localized include: TGA adverse event report formats, PSUR submission cycles and formats, and Australia-specific FSCA notification templates. The Sponsor is the TGA's sole point of contact, and the ARTG certificate is controlled by the Sponsor; therefore, a change of Sponsor (e.g., agent replacement) directly affects product sales in Australia. For multinational registrations, using a unified PMS database can significantly reduce redundant work and rectification risks, but differences in adverse event definitions across countries must be noted (e.g., Australia considers “non-serious unexpected device malfunction” as a reportable event). It is recommended that companies establish a global standard for data collection in the PMS plan and then tailor outputs to local regulations.

Frequently Asked Follow-up Questions

Q: What is the PMS reporting period in Australia?
A: For Class IIb, III, and AIMD devices, PSURs must be submitted every 2 years (annually for AIMD). If the product risk profile changes significantly, the TGA may require more frequent reports. Class I and IIa devices generally do not require PSUR submissions but must maintain PMS records for inspection. PSURs should be submitted by the anniversary date of ARTG listing.

Q: If the product has CE certification (EU), can PMS data be used directly for Australia?
A: Yes, partially, but adjustments are needed. For example, the EU PSUR format and content are similar to TGA requirements, but the TGA requires inclusion of global data (including local Australian data) and has shorter adverse event reporting timelines (24-hour initial report vs. EU's 48 hours). Additionally, Australia requires reporting of all serious events, including local non-serious events that could lead to serious consequences.

Q: What if the Sponsor does not cooperate with PMS work?
A: The Sponsor is fully responsible for PMS compliance. The manufacturer should specify data transfer obligations and reporting responsibilities in the contract. If the Sponsor fails to comply, the manufacturer can replace the Sponsor, but must reapply for an ARTG listing change. It is advisable to choose a local Sponsor with PMS experience in Australia.

Implementation Advice: In practice, companies should break this issue into five tasks: regulatory judgment, document preparation, evidence reuse, localization conversion, and post-market maintenance, rather than having one department compile documents ad hoc. This approach helps identify gaps earlier and aligns sales, R&D, quality, and regulatory teams on the target country's requirements. If planning to enter multiple markets simultaneously, companies should first create a unified core technical file, then supplement authorization, labeling, language, forms, and local agent documents for each country. The efficiency of multi-country registration often depends on a unified document framework from the outset, not the speed of submission to a single country. First confirm whether the product falls under the medical device regulatory scope of the target country. Then determine risk class, registration pathway, and applicant. Verify that technical documentation, quality system, and clinical evidence are mutually supportive. Clarify the local agent, authorized representative, and certificate control. Establish post-market change, renewal, and vigilance event maintenance mechanisms.